Angle plc’s Parsortix system, which captures and harvest circulating tumor cells (CTCs) for liquid biopsy analysis, has been used in breakthrough work by researchers at the University of New Mexico looking into the role of CTC gene expression in the progression of melanoma brain metastasis. The researchers used the Parsortix system to harvest CTCs for analysis and concluded that “… gene expression in CTCs could be pivotal to prescribing more targeted treatment based on the needs of the patient.”
Dexcom Inc. achieved the first integrations of an automated insulin delivery system (AID) approved for use in the U.S. with its G7 continuous glucose monitoring (CGM) integrating with Tandem Diabetes Care Inc.’s T2:slim X2, announced on Dec. 6, and integration with the Ilet Bionic Pancreas made by Beta Bionics Inc. revealed on Dec. 7.
Omini SA hopes that the multiplexed blood testing platform it is developing will transform the lives of patients suffering from heart failure. With its multiplex, sensor-based testing strip that simultaneously measures four key biomarkers from a single drop of blood, the company’s technology should increase the chance of a patient’s survival and reduce pressure on health care systems, Joanne Kanaan, CEO and co-founder of Omini, told BioWorld.
Brainspec Inc. received U.S. FDA 510(k) clearance for use of its artificial intelligence platform, Brainspec Core, in noninvasive measurement of brain chemistry using magnetic resonance spectroscopy (MRS).
Glucometrics Co. Ltd. is rolling out its self-developed application programming interface (API) for diabetes care in steps, and the latest partnership with G2E Co. Ltd. is underway to develop a smart insulin pen loaded with the interface.
The largest strike by U.S. health care workers, in early Oct. 2022, brought increased attention to the seriousness of the staff shortage in hospitals and the urgent need to address it. Multiple reports over the last 10 years have documented the impact of alarm fatigue on nurses, in particular, and its contribution to professional burnout and ongoing staffing issues. A bit counterintuitively, more integrated, continuous monitoring of vital signs reduces alarm fatigue for medical staff attending to post-surgical patients, a study by GE Healthcare Technologies Inc. and Cleveland Clinic found.
Medwatch Technologies Inc. reported a patent for the use of near infrared (NIR) spectroscopy, from collection of NIR LEDs surrounding a photo diode sensitive to wavelengths in the range 400 nm to 1650 nm, to noninvasively detect blood glucose concentrations, in a multi-sensing wearable device such as a watch or patch.
Nemaura Medical Inc. recently raised $6.5 million in non-dilutive funding through a clean debt facility with no warrants or convertible elements. The funding came from its existing lender and is expected to fund Nemaura’s ongoing efforts to commercialize its daily disposable, wearable glucose sensors.
Wearoptimo Pty. Ltd. saw the publication of a patent application for its method and system for analyzing measurements from a wearable patch with sensors connected to microstructures that when applied to the skin penetrate the stratum corneum and enter the viable epidermis.
At the same time it reported U.S. FDA clearance for bedside software to diagnose electrographic status epilepticus (ESE) seizures, Ceribell Inc. declared Claritypro the first ICU monitoring device to receive an NTAP reimbursement from the Centers for Medicare and Medicaid Services. The clearance of Claritypro to diagnose ESE follows receipt of an FDA breakthrough device designation in two different categories in the past year, setting the stage, Ceribell CEO Jane Chao told BioWorld, for expanded access to critical seizure diagnosis technology.
RSS
